ReviewInflammation2022
Macrophage-Targeted Nanomedicines for ARDS/ALI: Promise and Potential.
Review in Inflammation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global research landscape on nanotechnology in acute lung injury: a bibliometric analysis.Frontiers in digital health · 2025Pooled it
- Article
- The CXCR2-XBP1-NF-κB Axis Drives Inflammatory Amplification and Tissue Damage in Acute Lung Injury.Inflammation · 2026Article
- Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinformatics and Experimental Approach.Annals of transplantation · 2026Article
- Low-concentration cholesterol modification enhancesRSC advances · 2026Article
- Cyclic Strain and Macrophage-Mediated Transport Govern Micron-Sized PMAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of Integrated Stress Response-Related Biomarkers in Sepsis-Induced Acute Respiratory Distress Syndrome.Mediators of inflammation · 2026Article
- FPR1-dependent Pro-inflammatory Ccl4Respiratory research · 2025Article
- Investigating the impact of selegiline on the NF-kB/NLRP3/Caspase-1 signaling pathway in A549 lung epithelial cells exposed to lipopolysaccharide.Cytotechnology · 2025Article
- Targeting alveolar macrophages: a promising intervention for pulmonary infection and acute lung injury.Cellular & molecular biology letters · 2025Review
- Galactose-modified erythrocyte membrane fusion liposomes enable the targeted delivery of drug nanoparticles to the liver.RSC advances · 2025Article
- Phosphatidylserine-decorated delivery platform helps alleviate acute lung injury via potentiating macrophage targeting.Journal of lipid research · 2025Article
- Enhancing Lung Recovery: Inhaled Poly(lactic-ACS nano · 2025Article
- Primed Mesenchymal Stem Cells by IFN-γ and IL-1β Ameliorate Acute Respiratory Distress Syndrome through Enhancing Homing Effect and Immunomodulation.Biomolecules & therapeutics · 2025Article
- Relationship between VEGF to PEDF ratio and in-hospital mortality in acute respiratory distress syndrome patients.Scientific reports · 2025Article
- Macrophage‑driven pathogenesis in acute lung injury/acute respiratory disease syndrome: Harnessing natural products for therapeutic interventions (Review).Molecular medicine reports · 2025Review
- Mitochondrial transfer/transplantation in lung injury: mechanism, therapeutic potential, and clinical application.Frontiers in immunology · 2025Review
- Advances in Targeted Engineered Nanoparticle-Based Therapeutics for Respiratory Diseases: Current Insights and Future Perspectives.International journal of nanomedicine · 2025Review
- Screening of Phytocompounds Against the NF-kB Pathway Genes and Lung Elevated Proteins Associated with Acute Respiratory Distress Syndrome.Recent advances in inflammation & allergy drug discovery · 2025Article
- The role of quercetin in NLRP3-associated inflammation.Inflammopharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are characterized by progressive lung impairment typically triggered by inflammatory processes. The mortality toll for ARDS/ALI yet remains high because of the poor prognosis, lack of disease-specific inflammation management therapies, and prolonged hospitalizations. The urgency for the development of new effective therapeutic strategies has become acutely evident for patients with coronavirus disease 2019 (COVID-19) who are highly susceptible to ARDS/ALI. We propose that the lack of target specificity in ARDS/ALI of current treatments is one of the reasons for poor patient outcomes. Unlike traditional therapeutics, nanomedicine offers precise drug targeting to inflamed tissues, the capacity to surmount pulmonary barriers, enhanced interactions with lung epithelium, and the potential to reduce off-target and systemic adverse effects. In this article, we focus on the key cellular drivers of inflammation in ARDS/ALI: macrophages. We propose that as macrophages are involved in the etiology of ARDS/ALI and regulate inflammatory cascades, they are a promising target for new therapeutic development. In this review, we offer a survey of multiple nanomedicines that are currently being investigated with promising macrophage targeting potential and strategies for pulmonary delivery. Specifically, we will focus on nanomedicines that have shown engagement with proinflammatory macrophage targets and have the potential to reduce inflammation and reverse tissue damage in ARDS/ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.